Partner Ecosystem Virica's VSE platform, together with collaborations with FUJIFILM Biosciences and Ginkgo Bioworks, positions the company as a key supplier of yield-enhancing formulations for viral vectors and cell therapies. Target CMOs and gene-therapy manufacturers for joint development and licensing of VSE formulations and off the shelf media to boost production and streamline scale up.

Advanced Platform Virica launched Viric.AI, an active learning platform to optimize biomanufacturing. This appeals to teams seeking faster process development, reduced trial and error, and improved yields with less material usage. Propose integrating Viric.AI with client data to accelerate pipelines.

Product Expansion Off the shelf enhancer media solutions for AAV production and process robustness being developed with FUJIFILM Biosciences. This offers scalable media options for clients and can be cross sold with the VSE library to tailor solutions to specific vectors and cell lines.

Strategic Access Strategic access through Carleton University partnership and IRAP funding programs create opportunities for joint R and D initiatives and government funded projects. Approach local biotechs and universities with co development opportunities and grant alignment to de risk early stage contracts.

Value Proposition Value proposition centered on higher yields and improved quality to reduce manufacturing costs and improve patient access to therapies. Frame deals around faster timelines and more predictable production, targeting both commercial biotechs and established gene therapy and vaccine players.